<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307618</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02580</org_study_id>
    <secondary_id>NCI-2011-02580</secondary_id>
    <secondary_id>UCCRC-10-324-B</secondary_id>
    <secondary_id>CDR0000696233</secondary_id>
    <secondary_id>10-324-B</secondary_id>
    <secondary_id>8445</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <secondary_id>N01CM00071</secondary_id>
    <nct_id>NCT01307618</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>A Randomized Phase II Study of Multipeptide Vaccination With or Without IL-12, Then Combined With Regulatory T Cell Depletion Using Daclizumab in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase II trial is studying how well giving vaccine therapy together with or
      without recombinant interleukin-12 followed by daclizumab works in treating patients with
      melanoma that has spread to other places in the body. Vaccines made from peptides or antigens
      may help the body build an effective immune response to kill tumor cells. Recombinant
      interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating
      white blood cells to kill melanoma cells. Monoclonal antibodies, such as daclizumab, may
      decrease the number of regulatory T cells (T cells that suppress the activation of the
      immmune system) and may lead to a better immune response against melanoma. It is not yet
      known whether vaccine therapy is more effective with interleukin-12 and daclizumab in
      treating melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if admixture of IL-12 (recombinant interleukin-12) with vaccine emulsion will
      increase the frequency of vaccine-induced cluster of differentiation (CD)8+ T cells in the
      blood.

      II. To determine if administration of daclizumab will deplete CD4+CD25+ regulatory T cells
      from the peripheral and potentiate specific immune responses induced by vaccination.

      III. To determine if vaccination +/- daclizumab will be safe in this patient population.

      SECONDARY OBJECTIVES:

      I. To determine if vaccination +/- daclizumab will have clinical activity in patients with
      advanced melanoma.

      II. To determine if clinical response may be associated with particular gene expression
      profiles in the tumor microenvironment.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive multipeptide vaccination comprising recombinant MAGE-3.1 antigen,
      MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51
      intradermically (ID) or subcutaneously (SC) on days 1, 22, and 50.

      ARM II: Patients receive vaccination as in arm I with an admixture of recombinant
      interleukin-12 (IL-12) on days 1, 22, and 50.

      In both arms, patients are evaluated for immune response. Patients with partial response or
      stable disease may be immunized for up to a maximum of 1 year. Patients with complete
      response may be treated with 1 additional course of 3 vaccinations.

      EXPANDED COHORT: Additional patients are accrued to the arm with higher immune response and
      receive daclizumab IV over 15 minutes on day -7. Patients then receive vaccination as in arm
      I or arm II on days 1, 22, and 50 in the absence of disease progression or unacceptable
      toxicity.

      After completion of study therapy, patients are followed up every 8 weeks until disease
      progression and then at least every 3 months thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to lack of clinical efficacy and lack of drug supply, trial was closed early and
    correlative studies were not pursued further.
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Vaccine-induced CD8+ T Cells Assessed by Enzyme-linked Immunospot (ELISPOT)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Data before treatment and after 3 vaccines will be assessed using paired t-tests within each cohort as well as a two-sample t-test of the mean post-treatment levels between cohorts. Repeated measures analysis of variance or mixed effects models will be utilized to further characterize changes in the levels of circulating T cells over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Number of CD4+CD25+FoxP3+ Regulatory T Cells From Peripheral Blood</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Descriptive statistics and paired t-tests will be generated to describe the frequency and absolute number of CD4+CD25+FoxP3+ cells before and after daclizumab, and also at subsequent time points. Repeated measures of analysis of variance and mixed effects models will be used to further evaluate change in numbers over time, and to compare these changes between cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type and Grade of Toxicity Incidents Assessed by Common Toxicity Criteria Version 4.0 (CTCAE v4.0)</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Assessed by Modified World Health Organization (WHO) Criteria</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Median progression-free survival and the associated 95% confidence limits will be derived using the procedure described in Brookmeyer and Crowley.
The criteria for progressive disease are 1) appearance of new lesions, 2) 25% increase in the sum of the product of the largest perpendicular diameters of the indicator lesions, or 3) reappearance of any tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Assessed by Modified WHO Criteria</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Median overall survival and the associated 95% confidence limits will be derived using the procedure described in Brookmeyer and Crowley.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene Expression Profiles</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Gene cluster analysis will be performed using deoxyribonucleic acid (DNA)-Chip Analyzer (dCHIP) software and comparisons will be made before and after treatment in each individual patient, and between responders and non-responders. Attempts will be made to identify gene expression profiles that correlate with clinical outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage IV Skin Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm I (vaccine therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (vaccine therapy, IL-12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NA17.A2 Peptide Vaccine</intervention_name>
    <description>Given SC or ID</description>
    <arm_group_label>Arm I (vaccine therapy)</arm_group_label>
    <arm_group_label>Arm II (vaccine therapy, IL-12)</arm_group_label>
    <other_name>NA17.A2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant MAGE-3.1 Antigen</intervention_name>
    <description>Given SC or ID</description>
    <arm_group_label>Arm I (vaccine therapy)</arm_group_label>
    <arm_group_label>Arm II (vaccine therapy, IL-12)</arm_group_label>
    <other_name>MAGE-3</other_name>
    <other_name>MAGE-3.1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Interleukin-12</intervention_name>
    <description>Given SC or ID</description>
    <arm_group_label>Arm II (vaccine therapy, IL-12)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 Antigen</intervention_name>
    <description>Given SC or ID</description>
    <arm_group_label>Arm I (vaccine therapy)</arm_group_label>
    <other_name>Antigen LB39-AA</other_name>
    <other_name>Antigen SK29-AA</other_name>
    <other_name>MART-1 Tumor Antigen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (vaccine therapy)</arm_group_label>
    <arm_group_label>Arm II (vaccine therapy, IL-12)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed melanoma with evidence of metastatic
             disease either by radiologic or physical examination

               -  In-transit metastases are allowed

               -  Biopsy should be performed to reconfirm the diagnosis in cases of doubt

          -  Patients must have measurable disease

               -  For computed tomography (CT) imaging, this is defined as at least one lesion that
                  can be accurately measured in at least one dimension (longest diameter to be
                  recorded) as ≥ 20 mm by conventional techniques or as ≥ 10 mm by spiral CT scan

               -  For cutaneous lesions, these must be measurable with a ruler and documented
                  photographically with a ruler in place

          -  There are no limits on the number of prior therapies; patients must not have received
             a vaccine containing any of the melanoma antigen peptides, nor previously received
             daclizumab; at least 4 weeks must have passed since prior chemotherapy or radiation
             therapy (6 weeks for BCNU [carmustine] or mitomycin C)

          -  Life expectancy greater than or equal to 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Karnofsky ≥ 80%)

          -  Leukocytes ≥ 3,000/mcL

          -  Absolute neutrophil count (ANC) ≥ 1,500/mcL

          -  Hemoglobin ≥ 9 g/dL

          -  Platelets ≥ 100,000/mcL

          -  Creatinine ≤ 1.5 x upper limit of normal (ULN)

          -  Total bilirubin ≤ 1.5 x ULN

          -  Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) ≤
             2 x institutional ULN

          -  Lactate dehydrogenase (LDH) &lt; 1.25 x ULN

          -  Human leukocyte antigen (HLA) typing: patient must express HLA-A2, either by flow
             cytometry or by standard HLA typing

          -  Patient must agree to undergo biopsy of accessible tumor before and after therapy,
             when feasible, to study tumor cell properties and characteristics of immune cells; if
             a biopsy cannot be done, then a prior pathologic specimen from the patient must show
             tumor cells that are positive for melanosome specific antigen (HMB45) and MLANA
             (MelanA); the tumor must express at least 2 antigens in the vaccine for the patient to
             be eligible

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal, barrier method of birth control, or abstinence) prior to study entry, for
             the duration of treatment, and for 2 months after completion of treatment; a pregnancy
             test must be done and be negative for women of child-bearing potential; should a woman
             become pregnant or suspect she is pregnant while participating in this study, she
             should inform her treating physician immediately

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have had chemotherapy, biological or radiotherapy within 4 weeks (6 weeks
             for nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier

          -  Patients may not be receiving any other investigational agents

          -  Presence of untreated brain metastases; all patients must undergo brain imaging as
             part of the pre-study evaluation; only patients with no brain metastases, or with
             brain lesions successfully treated by stereotactic radiation or surgical removal
             without progression at 28-day follow-up and off corticosteroids for 4 weeks, will be
             eligible

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition IL-12 or other agents used in the study

          -  Concurrent systemic corticosteroids (except physiologic replacement doses) or other
             immunosuppressive drugs (eg. cyclosporin A)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, significant
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with IL-12; women of child-bearing age must be tested for
             urinary or serum beta-human chorionic gonadotropin (HCG)

          -  Patients with intrinsic immunosuppression, including seropositivity for human
             immunodeficiency virus (HIV) antibody; patients should be tested for HIV; HIV-positive
             patients are ineligible

          -  Psychiatric illness that may make compliance to the clinical protocol unmanageable or
             may compromise the ability of the patient to give informed consent; patients with
             clinical evidence of dementia should have a competent designee participate in decision
             making

          -  Serious concurrent infection, including active tuberculosis, hepatitis B, or hepatitis
             C; patients should be tested for hepatitis B surface antigen and hepatitis C antibody;
             patients who are hepatitis C antibody (Ab) positive can be eligible if they are
             polymerase chain reaction (PCR)-negative

          -  Active or history of autoimmune disease including but not limited to: rheumatoid
             arthritis (rheumatoid factor [RF]-positive with current or recent flare), inflammatory
             bowel disease, systemic lupus erythematosis (clinical evidence with antinuclear
             antibody [ANA] 1:80 or greater), ankylosing spondylitis, scleroderma, multiple
             sclerosis, autoimmune hemolytic anemia, and immune thrombocytopenic purpura;
             seropositivity alone will not be considered active autoimmunity; patients with
             immune-mediated hypothyrodisim and/or vitiligo are allowed

          -  Active gastrointestinal bleeding or uncontrolled peptic ulcer disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Gajewski</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2011</study_first_posted>
  <results_first_submitted>December 30, 2015</results_first_submitted>
  <results_first_submitted_qc>August 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2016</results_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Daclizumab</mesh_term>
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Vaccine Therapy)</title>
          <description>Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
MART-1 Antigen: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Vaccine Therapy, IL-12)</title>
          <description>Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
Recombinant Interleukin-12: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Vaccine Therapy)</title>
          <description>Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
MART-1 Antigen: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Vaccine Therapy, IL-12)</title>
          <description>Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
Recombinant Interleukin-12: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.86" spread="12.55"/>
                    <measurement group_id="B2" value="66.16" spread="15.11"/>
                    <measurement group_id="B3" value="62.01" spread="13.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Vaccine-induced CD8+ T Cells Assessed by Enzyme-linked Immunospot (ELISPOT)</title>
        <description>Data before treatment and after 3 vaccines will be assessed using paired t-tests within each cohort as well as a two-sample t-test of the mean post-treatment levels between cohorts. Repeated measures analysis of variance or mixed effects models will be utilized to further characterize changes in the levels of circulating T cells over time.</description>
        <time_frame>Up to 4 years</time_frame>
        <population>Due to lack of clinical efficacy and lack of drug supply, trial was closed early and frequency of vaccine-induced CD8+T cells was not measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Vaccine Therapy)</title>
            <description>Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
MART-1 Antigen: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vaccine Therapy, IL-12)</title>
            <description>Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
Recombinant Interleukin-12: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Vaccine-induced CD8+ T Cells Assessed by Enzyme-linked Immunospot (ELISPOT)</title>
          <description>Data before treatment and after 3 vaccines will be assessed using paired t-tests within each cohort as well as a two-sample t-test of the mean post-treatment levels between cohorts. Repeated measures analysis of variance or mixed effects models will be utilized to further characterize changes in the levels of circulating T cells over time.</description>
          <population>Due to lack of clinical efficacy and lack of drug supply, trial was closed early and frequency of vaccine-induced CD8+T cells was not measured.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Number of CD4+CD25+FoxP3+ Regulatory T Cells From Peripheral Blood</title>
        <description>Descriptive statistics and paired t-tests will be generated to describe the frequency and absolute number of CD4+CD25+FoxP3+ cells before and after daclizumab, and also at subsequent time points. Repeated measures of analysis of variance and mixed effects models will be used to further evaluate change in numbers over time, and to compare these changes between cohorts.</description>
        <time_frame>Up to 4 years</time_frame>
        <population>Due to lack of clinical efficacy and lack of drug supply, trial was closed early and absolute number of CD4+CD25+FoxP3+Regulatory T Cells from peripheral blood was not measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Vaccine Therapy)</title>
            <description>Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
MART-1 Antigen: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vaccine Therapy, IL-12)</title>
            <description>Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
Recombinant Interleukin-12: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Number of CD4+CD25+FoxP3+ Regulatory T Cells From Peripheral Blood</title>
          <description>Descriptive statistics and paired t-tests will be generated to describe the frequency and absolute number of CD4+CD25+FoxP3+ cells before and after daclizumab, and also at subsequent time points. Repeated measures of analysis of variance and mixed effects models will be used to further evaluate change in numbers over time, and to compare these changes between cohorts.</description>
          <population>Due to lack of clinical efficacy and lack of drug supply, trial was closed early and absolute number of CD4+CD25+FoxP3+Regulatory T Cells from peripheral blood was not measured.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Type and Grade of Toxicity Incidents Assessed by Common Toxicity Criteria Version 4.0 (CTCAE v4.0)</title>
        <time_frame>Up to 4 years</time_frame>
        <population>Patients who experienced any adverse event were counted.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Vaccine Therapy)</title>
            <description>Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
MART-1 Antigen: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vaccine Therapy, IL-12)</title>
            <description>Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
Recombinant Interleukin-12: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Type and Grade of Toxicity Incidents Assessed by Common Toxicity Criteria Version 4.0 (CTCAE v4.0)</title>
          <population>Patients who experienced any adverse event were counted.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal pain (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema multiforme (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site reaction (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal hemorrhage (Grade1 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal pain (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone pain (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death NOS (Grade 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dehydration (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea (Grade 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoalbuminemia (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleuritic pain (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteinuria (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric disorders (Grade 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival Assessed by Modified World Health Organization (WHO) Criteria</title>
        <description>Median progression-free survival and the associated 95% confidence limits will be derived using the procedure described in Brookmeyer and Crowley.
The criteria for progressive disease are 1) appearance of new lesions, 2) 25% increase in the sum of the product of the largest perpendicular diameters of the indicator lesions, or 3) reappearance of any tumor.</description>
        <time_frame>Up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Vaccine Therapy)</title>
            <description>Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
MART-1 Antigen: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vaccine Therapy, IL-12)</title>
            <description>Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
Recombinant Interleukin-12: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival Assessed by Modified World Health Organization (WHO) Criteria</title>
          <description>Median progression-free survival and the associated 95% confidence limits will be derived using the procedure described in Brookmeyer and Crowley.
The criteria for progressive disease are 1) appearance of new lesions, 2) 25% increase in the sum of the product of the largest perpendicular diameters of the indicator lesions, or 3) reappearance of any tumor.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" lower_limit="77">The upper limit of the 95% confidence interval was not reached.</measurement>
                    <measurement group_id="O2" value="64" lower_limit="63">The upper limit of the 95% confidence interval was not reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Assessed by Modified WHO Criteria</title>
        <description>Median overall survival and the associated 95% confidence limits will be derived using the procedure described in Brookmeyer and Crowley.</description>
        <time_frame>Up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Vaccine Therapy)</title>
            <description>Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
MART-1 Antigen: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vaccine Therapy, IL-12)</title>
            <description>Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
Recombinant Interleukin-12: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Assessed by Modified WHO Criteria</title>
          <description>Median overall survival and the associated 95% confidence limits will be derived using the procedure described in Brookmeyer and Crowley.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="804">The 95% confidence interval was not reached. Only one patient died and others were censored.</measurement>
                    <measurement group_id="O2" value="199" lower_limit="92">The upper limit of 95% confidence interval was not reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gene Expression Profiles</title>
        <description>Gene cluster analysis will be performed using deoxyribonucleic acid (DNA)-Chip Analyzer (dCHIP) software and comparisons will be made before and after treatment in each individual patient, and between responders and non-responders. Attempts will be made to identify gene expression profiles that correlate with clinical outcome.</description>
        <time_frame>Up to 4 years</time_frame>
        <population>Due to lack of clinical efficacy and lack of drug supply, trial was closed early and gene expression profiles was not measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Vaccine Therapy)</title>
            <description>Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
MART-1 Antigen: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vaccine Therapy, IL-12)</title>
            <description>Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
Recombinant Interleukin-12: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Gene Expression Profiles</title>
          <description>Gene cluster analysis will be performed using deoxyribonucleic acid (DNA)-Chip Analyzer (dCHIP) software and comparisons will be made before and after treatment in each individual patient, and between responders and non-responders. Attempts will be made to identify gene expression profiles that correlate with clinical outcome.</description>
          <population>Due to lack of clinical efficacy and lack of drug supply, trial was closed early and gene expression profiles was not measured.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Vaccine Therapy)</title>
          <description>Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
MART-1 Antigen: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Vaccine Therapy, IL-12)</title>
          <description>Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
NA17.A2 Peptide Vaccine: Given SC or ID
Recombinant MAGE-3.1 Antigen: Given SC or ID
Recombinant Interleukin-12: Given SC or ID
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tomas Gajewski</name_or_title>
      <organization>University of Chicago Comprehensive Cancer Center</organization>
      <phone>773-702-4601</phone>
      <email>tgajewsk@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

